Accès à distance ? S'identifier sur le proxy UCLouvain
Cetuximab in combination with oxaliplatin/5-fluorouracil (5FU)/folinic acid (FA) (FOLFOX-4) in the first-line treatment of patients with epidermal growth factor receptor (EGFR)-expressing metastatic colorectal cancer: An international phase II study.
Primary tabs
| Document type | Communication à un colloque (Conference Paper) – Abstract, Présentation orale avec comité de sélection |
|---|---|
| Publication date | 2005 |
| Language | Anglais |
| Conference | "41st Annual Meeting of the American-Society-of-Clinical-Oncology", Orlando (Fl) (May 13-17, 2005) |
| Journal information | "Journal of Clinical Oncology" - Vol. 23, no. 16, p. 254S-254S (2005) |
| Peer reviewed | yes |
| issn | 0732-183X |
| e-issn | 1527-7755 |
| Publisher | Amer Soc Clinical Oncology (Alexandria) |
| Affiliations |
UCL
- Cliniques universitaires Saint-Luc UCL - MD/IEPR - Institut d'éducation physique et de réadaptation UCL - MD/MINT - Département de médecine interne |
| Links |
| Bibliographic reference | Rubio, ED ; Humblet, Yves ; Tabernero, J. ; Van Cutsem, E. ; Cervantes, A. ; et. al. Cetuximab in combination with oxaliplatin/5-fluorouracil (5FU)/folinic acid (FA) (FOLFOX-4) in the first-line treatment of patients with epidermal growth factor receptor (EGFR)-expressing metastatic colorectal cancer: An international phase II study..41st Annual Meeting of the American-Society-of-Clinical-Oncology (Orlando (Fl), May 13-17, 2005). In: Journal of Clinical Oncology, Vol. 23, no. 16, p. 254S-254S (2005) |
|---|---|
| Permanent URL | http://hdl.handle.net/2078.1/61139 |